Metagenomi (MGX) Stock Price, News & Analysis

Company Overview

Metagenomi, Inc. (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors. The company works with manufacturers to enhance biofuel production, create greener chemical intermediates and develop more effective formulations for detergents, textiles and crop protection. In the biopharmaceutical realm, Metagenomi’s novel genome-editing components have the potential to drive next-generation gene therapies and precision medicine approaches by enabling targeted modifications in living cells.

Founded in 2019 and headquartered in South San Francisco, Metagenomi has rapidly expanded through strategic collaborations and research partnerships with industry leaders and academic institutions. The company’s management team combines deep expertise in genomics, computational biology and industrial biotechnology, positioning Metagenomi to serve global markets and address growing demand for sustainable, biologically derived solutions. As it advances its pipeline programs and broadens its partner network, Metagenomi continues to pursue breakthrough innovations that bridge metagenomics data with real-world manufacturing needs.

Key Stats

• Today's Range: $2.20 to $2.39
• 50-Day Range: $1.74 to $2.52
• 52-Week Range: $1.23 to $4.92
• Volume: 279,470 shs
• Average Volume: 518,364 shs
• Market Capitalization: $88.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Metagenomi Stock Analysis - MarketRank™

Metagenomi scored higher than 68% of companies evaluated by MarketBeat, and ranked 336th out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Metagenomi has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Metagenomi has a consensus price target of $10.00, representing about 321.9% upside from its current price of $2.37.

Amount of Analyst Coverage

Metagenomi has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Metagenomi are expected to decrease in the coming year, from ($2.46) to ($2.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Metagenomi is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Metagenomi is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Metagenomi has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.53% of the float of Metagenomi has been sold short.

Short Interest Ratio / Days to Cover

Metagenomi has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Metagenomi has recently decreased by 23.24%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Metagenomi does not currently pay a dividend.

Dividend Growth

Metagenomi does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.53% of the float of Metagenomi has been sold short.

Short Interest Ratio / Days to Cover

Metagenomi has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Metagenomi has recently decreased by 23.24%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.95

News Sentiment

Metagenomi has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Metagenomi this week, compared to 5 articles on an average week.

Search Interest

6 people have searched for MGX on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.

MarketBeat Follows

2 people have added Metagenomi to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Metagenomi insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.80% of the stock of Metagenomi is held by insiders. A high percentage of insider ownership can be a sign of company health.

MGX Stock Analysis - Frequently Asked Questions

How have MGX shares performed this year?

Metagenomi's stock was trading at $3.61 at the start of the year. Since then, MGX shares have decreased by 34.3% and is now trading at $2.37.

How were Metagenomi's earnings last quarter?

Metagenomi, Inc. (NASDAQ:MGX) posted its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.14. The company had revenue of $8.51 million for the quarter, compared to analysts' expectations of $7.72 million. Metagenomi had a negative trailing twelve-month return on equity of 37.84% and a negative net margin of 257.99%.

When did Metagenomi IPO?

Metagenomi (MGX) raised $94 million in an initial public offering on Friday, February 9th 2024. The company issued 6,250,000 shares at $15.00 per share.

How do I buy shares of Metagenomi?

Shares of MGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Metagenomi own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Metagenomi investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/30/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MGX
• Previous Symbol: NASDAQ:MGX
• CIK: 1785279
• Web: www.metagenomi.co
• Phone: 510-871-4880
• Fax: N/A
• Employees: 236
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Metagenomi: $10.00
• High Price Target: $12.00
• Low Price Target: $7.00
• Potential Upside/Downside: +321.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$78.06 million
• Net Margins: -257.99%
• Pretax Margin: -267.38%
• Return on Equity: -37.84%
• Return on Assets: -27.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.36
• Quick Ratio: 6.36

Sales & Book Value

• Annual Sales: $52.29 million
• Price / Sales: 1.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.28 per share
• Price / Book: 0.38

Miscellaneous

• Outstanding Shares: 37,530,000
• Free Float: 30,852,000
• Market Cap: $88.95 million
• Optionable: N/A
• Beta: -0.17